Therefore, we established a preclinical model of RAP (and used a novel dosing schedule to induce pancreatitis) to investigate the effect of recurrent inflammation on on-admission amylase activity, pro-inflammatory cytokine level (measuring IL-1ß), inflammatory cells (macrophage and T cells) and pancreatic morphology. The gene discussed is IL1B; the disease is pancreatitis.